KBD-1

KBD-1 directly interacts with purified recombinant KLHL41 protein with a K_D of 37.36 µM^[1].
KBD-1 (20 μM; 12 h) completely degrades BRD4 in RH30 human rhabdomyosarcoma cells^[1].
KBD-1 (20 μM) induces BRD4 degradation in RH30 human rhabdomyosarcoma cells via Cullin-RING ligase (CRL)-mediated ubiquitination and proteasomal degradation^[1].
KBD-1 (20 μM; 24 h) induces BRD4 degradation specifically in RD and RH30 human rhabdomyosarcoma cells (KLHL41-expressing) but not in OV90, A549, SW480, or HeLa non-muscle cancer cell lines^[1].
KBD-1 (40 μM; 24 h) induces cytotoxicity specifically in RD and RH30 human rhabdomyosarcoma cells but not in OV90, A549, SW480, or HeLa non-muscle cancer cell lines, with an IC₅₀ of 20 μM in myosarcoma cells^[1].
KBD-1 (20 μM; 12 h)-induced BRD4 degradation in RH30 human rhabdomyosarcoma cells is dependent on KLHL41 expression^[1].
KBD-1 (20 μM; 12 h) induces BRD4 degradation in HeLa human cervical adenocarcinoma cells only when KLHL41 is overexpressed, confirming KLHL41-dependent activity^[1].
KBD-1 induces BRD4 degradation in differentiated C2C12 mouse myocytes (high KLHL41 expression) but not in undifferentiated C2C12 myoblasts (low KLHL41 expression)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.